Levocetirizine (5mg) + Montelukast (10mg)
Ronycold-M Tablet is used in the treatment of sneezing and runny nose due to allergies.
10 tablets in 1 strip
Ronyd Healthcare Pvt Ltd
Image shown is a representation and may slightly vary from the actual product. Every effort is made to maintain accuracy of all information displayed.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Ronycold-M Tablet may be taken with or without food, but it is better to take it at a fixed time.
Ronycold-M Tablet is a combination of two medicines: Levocetirizine and Montelukast, which relieves sneezing and runny nose due to allergies. Levocetirizine is an antiallergic which blocks a chemical messenger (histamine) responsible for runny nose, watery eyes and sneezing. Montelukast is a leukotriene antagonist. It works by blocking another chemical messenger (leukotriene). This reduces inflammation (swelling) in the airways and nose, and improves symptoms.
Related Warnings
Ronycold-M Tablet may cause excessive drowsiness and calmness with alcohol.
Ronycold-M Tablet is probably safe to use during pregnancy.
Animal studies have shown low or no adverse effect on the foetus, however, there are limited human studies. Please consult your doctor.
Ronycold-M Tablet is probably safe to use during lactation. Limited human data suggests that the drug does not represent a significant risk to the baby.
Ronycold-M Tablet may make you feel dizzy, sleepy, tired, or decrease alertness. If this happens, do not drive.
Ronycold-M Tablet should be used with caution in patients with kidney disease. Dose adjustment of Ronycold-M Tablet may be needed. Please consult your doctor.
Use of Ronycold-M Tablet is not recommended in patients with severe kidney disease.
Ronycold-M Tablet should be used with caution in patients with severe liver disease. Dose adjustment of Ronycold-M Tablet may be needed. Please consult your doctor.
Limited information is available on the use of Ronycold-M Tablet in these patients. No dose adjustment is recommended in patients with mild to moderate liver disease.
